URGENT DRUG RECALL

July 24, 2026

Dear Healthcare Provider:

Baxter Healthcare Corporation is issuing an Urgent Drug Recall for one lot of cefazolin in dextrose injection listed below due to a customer report of particulate matter in the solution identified as cardboard. The affected lot number was distributed from 3/25/2025 to 6/30/2025 in the United States.

Affected Product

Product Code	Product Description	Lot Number	Expiration Date	NDC Number
2G3508	Cefazolin in Dextrose Injection, USP, 2g / 100mL (20mg / mL) Single-Dose Infusion Bag in 100mL GALAXY Plastic Container, Frozen Premix	LD175708	14-Feb-2027	0338-3508-41



Figure 1. Product Label



Figure 2. Carton Label

Hazard Involved

The use of the defective product has a reasonable probability of causing pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or phlebitis (inflammation of the walls of veins, which may lead to clotting). Systemically, foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis (breakdown of blood cells). To date, Baxter has not received any reports of adverse events related to this issue.

Actions to be Taken by Customers

1. Immediately locate, isolate, and cease all use of the affected lot number of the product. The lot number and expiration date can be found on the individual product (refer to *Figure 1*) and shipping carton (refer to *Figure 2*) as pictured on page 1.
2. Contact Baxter Healthcare Center for Service to arrange for return and replacement product at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Please have your Baxter 8-digit ship-to account number, product code, lot number, and quantity of product to be returned ready when calling.
3. Acknowledge receipt of this notification by following the instructions in the corresponding email, even if you have no remaining inventory. Acknowledging receipt will prevent you from receiving repeat notices. If you do not complete the acknowledgement, you will receive a phone call from Accenture LLP on behalf of Baxter to confirm your receipt of this notification.
4. Please forward a copy of this communication to the director of pharmacy, director of nursing, director of purchasing, facility risk manager, and any other departments within your institution who use the affected product.

Further Information and Support

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

The United States Food and Drug Administration (FDA) has been notified of this action. Any product quality complaints or adverse events experienced with the use of these products may be reported using one of the following options:

- Contacting Baxter Product Surveillance at the Baxter product feedback portal at https://productfeedback.baxter.com, or emailing Baxter at corporate_product_complaints_round_lake@baxter.com
- Reporting to the FDA MedWatch Serious Injury Reporting Program:
    - **Online:** By completing and submitting the report at www.accessdata.fda.gov/scripts/medwatch
    - **Regular mail or Fax:** Download the form from www.fda.gov/MedWatch/getforms.htm or call 800-332-1088 to request a reporting form, then complete and mail it to the address on the pre-addressed form or submit by fax to 800-332-0178

We apologize for any inconvenience this may cause you and your staff.

Sincerely,

Craig Plunkard
Senior Director, Quality
Baxter Healthcare Corporation